SK30797A3 - Use of il-4 for potentiation of chemotherapeutic agents - Google Patents
Use of il-4 for potentiation of chemotherapeutic agents Download PDFInfo
- Publication number
- SK30797A3 SK30797A3 SK307-97A SK30797A SK30797A3 SK 30797 A3 SK30797 A3 SK 30797A3 SK 30797 A SK30797 A SK 30797A SK 30797 A3 SK30797 A3 SK 30797A3
- Authority
- SK
- Slovakia
- Prior art keywords
- chemotherapeutic agents
- cancer
- hodgkin
- patients
- enhancing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30192994A | 1994-09-07 | 1994-09-07 | |
US08/321,504 US5716612A (en) | 1994-09-07 | 1994-10-12 | Use of IL-4 for potentiation of chemotherapeutic agents |
PCT/US1995/010988 WO1996007422A1 (en) | 1994-09-07 | 1995-09-07 | Use of il-4 for potentiation of chemotherapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SK30797A3 true SK30797A3 (en) | 1997-11-05 |
Family
ID=26972669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK307-97A SK30797A3 (en) | 1994-09-07 | 1995-09-07 | Use of il-4 for potentiation of chemotherapeutic agents |
Country Status (14)
Country | Link |
---|---|
US (1) | US5716612A (fi) |
EP (1) | EP0805688A1 (fi) |
JP (1) | JPH09510737A (fi) |
CN (1) | CN1157571A (fi) |
AU (1) | AU3541295A (fi) |
CA (1) | CA2199262A1 (fi) |
CZ (1) | CZ68297A3 (fi) |
FI (1) | FI970931A (fi) |
HU (1) | HUT76665A (fi) |
MX (1) | MX9701478A (fi) |
NO (1) | NO971043L (fi) |
PL (1) | PL319034A1 (fi) |
SK (1) | SK30797A3 (fi) |
WO (1) | WO1996007422A1 (fi) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1981868A (zh) * | 2000-03-31 | 2007-06-20 | 拜奥根Idec公司 | 抗细胞因子抗体或拮抗剂与抗-cd20在b细胞淋巴瘤治疗中的联合应用 |
WO2002032400A1 (en) * | 2000-10-16 | 2002-04-25 | Neopharm, Inc. | Liposomal formulation of mitoxantrone |
WO2004091499A2 (en) * | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Intracellular formation of peptide conjugates |
US7932052B1 (en) * | 2006-07-24 | 2011-04-26 | The Regents Of The University Of Michigan | Use of methanobactin |
WO2017175200A1 (en) | 2016-04-08 | 2017-10-12 | The Regents Of The University Of California | Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT83761B (pt) * | 1985-11-19 | 1989-06-30 | Schering Biotech Corp | Metodo para a producao de interleuquina-4 de mamifero |
US4958007A (en) * | 1988-05-17 | 1990-09-18 | Schering-Plough Corp. | Extraction of human interleukin-4- from bacteria |
KR100191223B1 (ko) * | 1989-07-28 | 1999-06-15 | 둘락 노먼 씨. | 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물 |
DE68916444T2 (de) * | 1989-10-31 | 1994-11-03 | Schering Corp., Kenilworth, N.J. | Sekretorische e-coli-stämme. |
ATE145556T1 (de) * | 1990-09-06 | 1996-12-15 | Schering Corp | Verwendung von interleukin-4 zur behandlung der festen tumoren |
EP0490006B1 (en) * | 1990-12-13 | 1994-06-22 | Schering-Plough | Pharmaceutical compositions for the treatment of B-cell malignancies |
JPH05964A (ja) * | 1991-06-19 | 1993-01-08 | Tonen Corp | 骨疾患治療薬及び高カルシウム血症治療薬 |
-
1994
- 1994-10-12 US US08/321,504 patent/US5716612A/en not_active Expired - Fee Related
-
1995
- 1995-09-07 JP JP8509558A patent/JPH09510737A/ja active Pending
- 1995-09-07 CN CN95194962A patent/CN1157571A/zh active Pending
- 1995-09-07 CZ CZ97682A patent/CZ68297A3/cs unknown
- 1995-09-07 MX MX9701478A patent/MX9701478A/es unknown
- 1995-09-07 WO PCT/US1995/010988 patent/WO1996007422A1/en not_active Application Discontinuation
- 1995-09-07 PL PL95319034A patent/PL319034A1/xx unknown
- 1995-09-07 AU AU35412/95A patent/AU3541295A/en not_active Abandoned
- 1995-09-07 CA CA002199262A patent/CA2199262A1/en not_active Abandoned
- 1995-09-07 SK SK307-97A patent/SK30797A3/sk unknown
- 1995-09-07 HU HU9701243A patent/HUT76665A/hu unknown
- 1995-09-07 EP EP95932344A patent/EP0805688A1/en not_active Withdrawn
-
1997
- 1997-03-05 FI FI970931A patent/FI970931A/fi unknown
- 1997-03-06 NO NO971043A patent/NO971043L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPH09510737A (ja) | 1997-10-28 |
CN1157571A (zh) | 1997-08-20 |
NO971043D0 (no) | 1997-03-06 |
FI970931A0 (fi) | 1997-03-05 |
MX9701478A (es) | 1997-05-31 |
NO971043L (no) | 1997-05-06 |
WO1996007422A1 (en) | 1996-03-14 |
CA2199262A1 (en) | 1996-03-14 |
PL319034A1 (en) | 1997-07-21 |
FI970931A (fi) | 1997-03-05 |
EP0805688A1 (en) | 1997-11-12 |
CZ68297A3 (en) | 1997-10-15 |
AU3541295A (en) | 1996-03-27 |
HUT76665A (en) | 1997-10-28 |
US5716612A (en) | 1998-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wing et al. | Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients | |
Root et al. | Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients | |
Rabinowitz et al. | Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support | |
US5437863A (en) | Method of enhancing the growth of gut epithelial cells by administration of a cytokine such as interleukin II | |
CN1845757B (zh) | 细胞因子混合物在制备由于预敏化癌症的药物中的用途和用于治疗癌症的药物组合物 | |
HU215389B (hu) | Eljárás hatóanyagként IL-4-et tartalmazó tömött tumorok kezelésére alkalmas gyógyszerkészítmények előállítására | |
EP1608397B1 (en) | S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment | |
Rahman et al. | Cytokines and their role as immunotherapeutics and vaccine Adjuvants: The emerging concepts | |
Sredni et al. | Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin. | |
SK30797A3 (en) | Use of il-4 for potentiation of chemotherapeutic agents | |
CN1064018A (zh) | 治疗细胞增殖紊乱所用组合物的制备方法 | |
Bui et al. | Differential disposition of soluble and liposome-formulated human recombinant interleukin-7: effects on blood lymphocyte population in guinea pigs | |
Tate et al. | Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects | |
Mitsuyasu et al. | Clinical role of granulocyte-macrophage colony-stimulating factor | |
Davidkova et al. | Endogenous production of tumor necrosis factor in normal mice orally treated with DEODAN—a preparation from Lactobacillus bulgaricus “LB51” | |
Kimball et al. | Enhancement of in vitro lipopolysaccharide-stimulated interleukin-1 production by levamisole | |
WO2013016634A1 (en) | Use of il-12 to generate endogenous erythropoietin | |
Troussard et al. | Human recombinant granulocyte‐macrophage colony stimulating factor (hrGM‐CSF) improves double hemibody irradiation (DHBI) tolerance in patients with stage III multiple myeloma: A pilot study | |
HUT63062A (en) | Process for producing pharmaceutical compositions increasing the immune response and comprising il-4 | |
WO2019126384A1 (en) | Effective il-12 dosing regimens | |
Itälä et al. | Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections | |
EP0561927B1 (en) | Pharmaceutical compositions for the treatment of b-cell malignancies | |
Gol et al. | Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo | |
Takada et al. | The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer | |
Miles et al. | The use of hematopoietic hormones in HIV infection and AIDS-related malignancies |